SGMO
SANGAMO THERAPEUTICS, INC
$0.1500
0.00%
No data for this timeframe.
Vol
Inst. Holders41 funds
Inst. Value$12.3M
Inst. Activity8 buys / 2 sells
Insider Activity0B / 2S
Insider Net $-$106.9K
SEC Reports2
Press Releases2
Exchange OTC·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001001233·Prev Close $0.1500
Recent Activity
May 25, 2026
Insider
Davis Gregory D surrendered for taxes 1,630 shares
Head of Research & Technology @ $0.1743 ($284.11)
May 25, 2026
Insider
Jain Nikunj surrendered for taxes 1,919 shares
Principal Accounting Officer @ $0.1743 ($334.48)
May 25, 2026
Insider
Dubois-Stringfellow Nathalie surrendered for taxes 4,036 shares
SVP-CHIEF DEVELOPMENT OFFICER @ $0.1743 ($703.47)
May 18, 2026
earnings_calendar
SGMO Q1 2026 Earnings After Market Close — 2026-05-18
Apr 29, 2026
SEC
Sangamo Therapeutics received a delisting notice from Nasdaq on April 28, 2026, due to its stock price remaining below $
8-K — Impact 8/10
Apr 23, 2026
SEC
Two senior executives at Sangamo Therapeutics — the Chief Development Officer and Head of Research & Technology — sold s
CLUSTER — Impact 3/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
3,836,665 shares ($947.3K)
Inst.
CHARLES SCHWAB INVESTMENT MANAGEMENT — ADD
2,352,360 shares ($580.8K)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$1.67 (Feb 2026)
Current $0.1500
Low $1.00
Median $2.00
High $2.00
3 analysts
$1.00
$2.00
Analyst Ratings
3Strong Buy
5Buy
3Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 ▲ +23.1% | $-0.05 — $-0.05 | 38% YoY | 1 |
| Next Q | $-0.05 ▲ +28.6% | $-0.05 — $-0.05 | 55% YoY | 1 |
| Current FY | $-0.20 ▲ +23.1% | $-0.20 — $-0.20 | 49% YoY | 1 |
| Next FY | $0.01 | $-0.10 — $0.11 | 102% YoY | 2 |
Latest Reports
BEARISH
8-K
8/10
Sangamo Therapeutics received a delisting notice from Nasdaq on April 28, 2026, due to its stock price remaining below $
Apr 29, 2026
NEUTRAL
CLUSTER
3/10
Two senior executives at Sangamo Therapeutics — the Chief Development Officer and Head of Research & Technology — sold s
Apr 23, 2026
MIXED
Press
6/10
Sangamo Therapeutics reported mixed financial results for 2025, with declining annual revenue and widening net losses, b
Mar 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BARCLAYS PLC | — | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $3.1M | — |
| TWO SIGMA INVESTMENTS, LP | $1.5M | ADD |
| BALYASNY ASSET MANAGEMENT L.P. | $1.3M | — |
| BlackRock, Inc. | $1.1M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 25, 2026 | Davis Gregory | F | $284.11 |
| May 25, 2026 | Jain Nikunj | F | $334.48 |
| May 25, 2026 | Dubois-Stringfellow Nathalie | F | $703.47 |
| May 25, 2026 | Willoughby Scott | F | $703.47 |
| May 25, 2026 | Macrae Sandy | F | $2.2K |
41 institutional holders with $12.3M total value (49,580,319 shares) as of 2026-Q1. Top holders: BARCLAYS, VANGUARD, TWO. Net buying activity: 8 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BARCLAYS PLC | 1 | $0.00 | 0.0% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 12,704,408 | $3.1M | 25.6% | — |
| 3 | TWO SIGMA INVESTMENTS, LP | 6,270,441 | $1.5M | 12.6% | ADD +91.8% |
| 4 | BALYASNY ASSET MANAGEMENT L.P. | 5,288,097 | $1.3M | 10.7% | — |
| 5 | BlackRock, Inc. | 4,547,848 | $1.1M | 9.2% | — |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 3,836,665 | $947.3K | 7.7% | TRIM -54.5% |
| 7 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,352,360 | $580.8K | 4.7% | ADD +37.3% |
| 8 | VANGUARD FIDUCIARY TRUST CO | 2,310,297 | $570.6K | 4.7% | — |
| 9 | BANK OF AMERICA CORP /DE/ | 1,838,390 | $452.2K | 3.7% | DOUBLED +1856.1% |
| 10 | STATE STREET CORP | 1,694,783 | $418.4K | 3.4% | ADD +25.0% |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,687,463 | $416.6K | 3.4% | — |
| 12 | Invesco Ltd. | 1,045,232 | $258.1K | 2.1% | ADD +40.6% |
| 13 | HighTower Advisors, LLC | 706,481 | $174.4K | 1.4% | — |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 603,100 | $150.8K | 1.2% | — |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 461,800 | $115.5K | 0.9% | — |
| 16 | MORGAN STANLEY | 423,265 | $104.5K | 0.9% | TRIM -28.4% |
| 17 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 400,000 | $99.0K | 0.8% | — |
| 18 | CANADA PENSION PLAN INVESTMENT BOARD | 397,100 | $98.0K | 0.8% | ADD +57.6% |
| 19 | GOLDMAN SACHS GROUP INC | 377,287 | $93.2K | 0.8% | — |
| 20 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 361,277 | $89.2K | 0.7% | ADD +74.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 8,430,323 | 3,836,665 | -54.5% | $947.3K | 2026-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,713,331 | 2,352,360 | +37.3% | $580.8K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 93,984 | 1,838,390 | +1856.1% | $452.2K | 2026-Q1 |
| STATE STREET CORP | ADD | 1,355,583 | 1,694,783 | +25.0% | $418.4K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 251,900 | 397,100 | +57.6% | $98.0K | 2026-Q1 |
| GROUP ONE TRADING LLC | TRIM | 500,179 | 340,305 | -32.0% | $84.0K | 2026-Q1 |
| CAPTRUST FINANCIAL ADVISORS | DOUBLED | 29,255 | 268,755 | +818.7% | $66.4K | 2026-Q1 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | ADD | 45,300 | 72,000 | +58.9% | $21.6K | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 50,357 | 68,778 | +36.6% | $17.0K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 2,900 | 7,900 | +172.4% | $2.0K | 2026-Q1 |
| TWO SIGMA INVESTMENTS, LP | ADD | 2,479,186 | 4,755,995 | +91.8% | $2.0M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 592,153 | 423,752 | -28.4% | $178.0K | 2025-Q4 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | ADD | 199,902 | 348,038 | +74.1% | $146.2K | 2025-Q4 |
| PNC FINANCIAL SERVICES GROUP, INC. | DOUBLED | 35,000 | 150,000 | +328.6% | $63.0K | 2025-Q4 |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | DOUBLED | 10,300 | 45,300 | +339.8% | $20.1K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 6,839,434 | 10,182,463 | +48.9% | $6.9M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 877,079 | 2,479,186 | +182.7% | $1.7M | 2025-Q3 |
| WASATCH ADVISORS LP | NEAR_EXIT | 8,084,419 | 1,426,453 | -82.4% | $960.6K | 2025-Q3 |
| STATE STREET CORP | ADD | 836,452 | 1,355,583 | +62.1% | $912.9K | 2025-Q3 |
| CITADEL ADVISORS LLC | DOUBLED | 195,261 | 1,208,415 | +518.9% | $813.7K | 2025-Q3 |
| GROUP ONE TRADING LLC | DOUBLED | 232,170 | 502,004 | +116.2% | $338.0K | 2025-Q3 |
| FMR LLC | TRIM | 582,336 | 252,880 | -56.6% | $170.3K | 2025-Q3 |
| Cerity Partners LLC | DOUBLED | 50,000 | 179,668 | +259.3% | $121.0K | 2025-Q3 |
| Russell Investments Group, Ltd. | ADD | 33,148 | 50,653 | +52.8% | $34.1K | 2025-Q3 |
| Vanguard Personalized Indexing Management, LLC | ADD | 23,735 | 35,511 | +49.6% | $23.9K | 2025-Q3 |
5 unique insiders with 22 transactions. Net insider value: -$106.9K ($0.00 bought, $106.9K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 25, 2026 | Davis Gregory D | Head of Research & Technology | TAX W/H | 1,630 | $0.1743 | $284.11 |
| May 25, 2026 | Jain Nikunj | Principal Accounting Officer | TAX W/H | 1,919 | $0.1743 | $334.48 |
| May 25, 2026 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | TAX W/H | 4,036 | $0.1743 | $703.47 |
| May 25, 2026 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | TAX W/H | 4,036 | $0.1743 | $703.47 |
| May 25, 2026 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | TAX W/H | 12,613 | $0.1743 | $2.2K |
| Apr 22, 2026 | Davis Gregory D | Head of Research & Technology | SELL | 69,827 | $0.2534 | $17.7K |
| Apr 21, 2026 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | SELL | 345,942 | $0.2578 | $89.2K |
| Apr 1, 2026 | Jain Nikunj | Principal Accounting Officer | AWARD | 225,000 | — | — |
| Apr 1, 2026 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | AWARD | 2,500,000 | — | — |
| Apr 1, 2026 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | AWARD | 800,000 | — | — |
| Apr 1, 2026 | Davis Gregory D | Head of Research & Technology | AWARD | 225,000 | — | — |
| Apr 1, 2026 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | AWARD | 800,000 | — | — |
| Feb 25, 2026 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | TAX W/H | 12,354 | $0.4700 | $5.8K |
| Feb 25, 2026 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | TAX W/H | 33,637 | $0.4700 | $15.8K |
| Feb 25, 2026 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | TAX W/H | 12,354 | $0.4700 | $5.8K |
| Feb 25, 2026 | Jain Nikunj | Principal Accounting Officer | TAX W/H | 5,119 | $0.4700 | $2.4K |
| Feb 25, 2026 | Davis Gregory D | Head of Research & Technology | TAX W/H | 5,119 | $0.4700 | $2.4K |
| Feb 24, 2026 | Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | TAX W/H | 2,063 | $0.4725 | $974.77 |
| Feb 24, 2026 | Macrae Sandy | PRESIDENT, CEO AND DIRECTOR | TAX W/H | 5,291 | $0.4725 | $2.5K |
| Feb 24, 2026 | Willoughby Scott B. | SVP, CHIEF LEGAL OFFICER, SECY | TAX W/H | 1,650 | $0.4725 | $779.63 |
| Feb 24, 2026 | Jain Nikunj | Principal Accounting Officer | TAX W/H | 666 | $0.4725 | $314.69 |
| Feb 24, 2026 | Davis Gregory D | Head of Research & Technology | TAX W/H | 832 | $0.4725 | $393.12 |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
Historical analyst distribution (last covering-analyst action Feb 2026): 73% buy across 11 analysts — 3 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$1.67 mean target (Feb 2026)
$1.00 Low
$2.00 High
| Metric | Value |
|---|---|
| Current Price | $0.1500 |
| Target Low | $1.00 |
| Target Mean | $1.67 |
| Target Median | $2.00 |
| Target High | $2.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.05 | $-0.05 | $-0.05 | 37.5% | +23.1% | 1↑ 0↓ | $0.0B | -37.7% | 1 |
| Next Q 2026-09-30 |
$-0.05 | $-0.05 | $-0.05 | 54.5% | +28.6% | 1↑ 0↓ | $0.0B | 1592.5% | 1 |
| Current FY 2026-12-31 |
$-0.20 | $-0.20 | $-0.20 | 48.9% | +23.1% | 1↑ 0↓ | $0.1B | 41.2% | 1 |
| Next FY 2027-12-31 |
$0.01 | $-0.10 | $0.11 | 102.5% | — | 1↑ 0↓ | $0.1B | 132.1% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.050 | |
| 7d ago | $-0.065 | +0.015 |
| 30d ago | $-0.065 | +0.015 |
| 60d ago | $-0.040 | -0.010 |
| 90d ago | $-0.040 | -0.010 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| May 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Apr 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Feb 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Jan 1, 2026 | 3 | 5 | 4 | 0 | 0 | 67% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 18, 2026
earnings_calendar
SGMO Q1 2026 Earnings After Market Close — 2026-05-18
May 14, 2026
earnings_calendar
SGMO Q1 2026 Earnings After Market Close — 2026-05-14
May 4, 2026
short_volume
Short Volume: SGMO — 60.8% short (36.0M / 59.2M)
Short: 35,977,841 | Exempt: 556,482 | TRF Vol: 59,178,414 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
routine
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
SANGAMO THERAPEUTICS TO PRESENT PIPELINE AND TECHNOLOGY ADVANCES AT THE 29TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)
Apr 29, 2026
other
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
Sangamo’s common stock to transition trading from The Nasdaq Capital Market to OTCQB Venture Market beginning May 5, 2026
Apr 16, 2026
short_volume
Short Volume: SGMO — 56.1% short (1.1M / 2.0M)
Short: 1,116,727 | Exempt: 9,977 | TRF Vol: 1,990,082 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
Clinical Trial
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
Phase Phase 2 — COMPLETED
Apr 8, 2026
short_volume
Short Volume: SGMO — 58.7% short (2.1M / 3.7M)
Short: 2,148,758 | Exempt: 184,947 | TRF Vol: 3,661,220 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Apr 7, 2026
short_volume
Short Volume: SGMO — 56.7% short (2.6M / 4.6M)
Short: 2,586,333 | Exempt: 359,604 | TRF Vol: 4,558,043 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_volume
Short Volume: SGMO — 66.2% short (2.3M / 3.5M)
Short: 2,336,782 | Exempt: 388,482 | TRF Vol: 3,531,288 | Short Ratio: 66.2% | Off-exchange volume (dark pool + OTC)
Mar 31, 2026
short_volume
Short Volume: SGMO — 62.3% short (10.0M / 16.0M)
Short: 9,958,386 | Exempt: 1,287,847 | TRF Vol: 15,975,179 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
Mar 30, 2026
earnings
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
Sangamo Therapeutics reports recent business highlights and fourth quarter and full year 2025 financial results
Mar 30, 2026
earnings_calendar
SGMO Q4 2025 Earnings After Market Close — 2026-03-30
Mar 30, 2026
short_volume
Short Volume: SGMO — 57.1% short (3.0M / 5.2M)
Short: 2,959,999 | Exempt: 16,612 | TRF Vol: 5,187,726 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
short_volume
Short Volume: SGMO — 76.0% short (3.2M / 4.2M)
Short: 3,207,602 | Exempt: 3,345 | TRF Vol: 4,221,217 | Short Ratio: 76.0% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
short_volume
Short Volume: SGMO — 57.0% short (1.8M / 3.2M)
Short: 1,800,066 | Exempt: 487 | TRF Vol: 3,158,316 | Short Ratio: 57.0% | Off-exchange volume (dark pool + OTC)